Page 184 - Read Online

Bradshaw et al. Vessel Plus 2023;7:35 https://dx.doi.org/10.20517/2574-1209.2023.121 Page 17 of 21

29. Caparrelli DJ, Cattaneo Ii SM, Bethea BT, et al. Pharmacological preconditioning ameliorates neurological injury in a model of spinal
cord ischemia. Ann Thorac Surg 2002;74:838-45. DOI
30. O’Rourke B. Myocardial K ATP channels in preconditioning. Circ Res 2000;87:845-55. DOI PubMed
+
31. O’Rourke B. Evidence for mitochondrial K channels and their role in cardioprotection. Circ Res 2004;94:420-32. DOI PubMed
PMC
32. Garlid KD. Opening mitochondrial K in the heart - what happens, and what does not happen. Basic Res Cardiol 2000;95:275-9.
ATP
DOI
33. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-
+
sensitive K channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606:1-21. DOI PubMed
34. Hu H, Sato T, Seharaseyon J, et al. Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K ATP
channels and native cardiac mitochondrial K ATP channels. Mol Pharmacol 1999;55:1000-5. DOI
35. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K channels and myocardial preconditioning. Circ
+
Res 1999;84:973-9. DOI
36. Kulawiak B, Szewczyk A. Current challenges of mitochondrial potassium channel research. Front Physiol 2022;13:907015. DOI
PubMed PMC
37. Tseng GN, Hoffman BF. Actions of pinacidil on membrane currents in canine ventricular myocytes and their modulation by
intracellular ATP and cAMP. Pflugers Arch 1990;415:414-24. DOI PubMed
38. Inagaki N, Gonoi T, Clement JP, et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-
+
sensitive K channels. Neuron 1996;16:1011-7. DOI
39. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol
1999;61:337-62. DOI
40. Shyng SL, Nichols CG. Octameric stoichiometry of the K channel complex. J Gen Physiol 1997;110:655-64. DOI PubMed PMC
ATP
41. Sellitto AD, Maffit SK, Al-Dadah AS, et al. Diazoxide maintenance of myocyte volume and contractility during stress: evidence for a
non-sarcolemmal K channel location. J Thorac Cardiovasc Surg 2010;140:1153-9. DOI PubMed PMC
ATP
42. Garlid KD, Halestrap AP. The mitochondrial K channel - fact or fiction? J Mol Cell Cardiol 2012;52:578-83. DOI PubMed
ATP
PMC
43. Hu X, Xu X, Huang Y, et al. Disruption of sarcolemmal ATP-sensitive potassium channel activity impairs the cardiac response to
systolic overload. Circ Res 2008;103:1009-17. DOI PubMed PMC
44. Flagg TP, Kurata HT, Masia R, et al. Differential structure of atrial and ventricular K ATP : atrial K ATP channels require SUR1. Circ Res
2008;103:1458-65. DOI PubMed PMC
45. Paggio A, Checchetto V, Campo A, et al. Identification of an ATP-sensitive potassium channel in mitochondria. Nature
2019;572:609-13. DOI PubMed PMC
+
46. Garlid KD, Paucek P. Mitochondrial potassium transport: the K cycle. Biochim Biophys Acta 2003;1606:23-41. DOI
47. Kravenska Y, Checchetto V, Szabo I. Routes for potassium ions across mitochondrial membranes: a biophysical point of view with
+
special focus on the ATP-sensitive K channel. Biomolecules 2021;11:1172. DOI PubMed PMC
48. Flagg TP, Enkvetchakul D, Koster JC, Nichols CG. Muscle KATP channels: recent insights to energy sensing and myoprotection.
Physiol Rev 2010;90:799-829. DOI PubMed PMC
49. Wlson WR, Okun R. The acute hemodynamic effects of diazoxide in man. Circulation 1963;28:89-93. DOI
50. Rubin AA, Roth FE, Taylor RM, Rosenkilde H. Pharmacology of diazoxide, an antihypertensive, nondiuretic benzothiadiazine. J
Pharmacol Exp Ther 1962;136:344-52. Avaliable from: https://jpet.aspetjournals.org/content/136/3/344.short [Last accessed on 26
Dec 2023].
51. Diazoxide. Br Med J 1972;4:417-8. PubMed
52. Kumar GK, Dastoor FC, Rodriguez Robayo J, Razzaque MA. Side effects of diazoxide. JAMA 1976;235:275-6. DOI
53. Komatsu Y, Nakamura A, Takihata M, et al. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic
hypoglycemia. Endocr J 2016;63:311-4. DOI
54. Gray KD, Dudash K, Escobar C, et al; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee.
Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018;38:1496-502. DOI PubMed PMC
55. Brito PC, Lopes V, Antunes E, Alves M, Gonçalves I, Matos AC. Hypoglycemia in a non-diabetic patient and the side effects of
diazoxide use. Cureus 2023;15:e36804. DOI PubMed PMC
56. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev
1997;77:1165-232. DOI PubMed
57. Aziz Q, Li Y, Anderson N, Ojake L, Tsisanova E, Tinker A. Molecular and functional characterization of the endothelial ATP-
sensitive potassium channel. J Biol Chem 2017;292:17587-97. DOI PubMed PMC
58. Wrzosek A, Gałecka S, Żochowska M, Olszewska A, Kulawiak B. Alternative targets for modulators of mitochondrial potassium
channels. Molecules 2022;27:299. DOI PubMed PMC
59. Wang J, Papanicolaou K, Tryon R, et al. Kir1.1 and SUR1 are not implicated as subunits of an adenosine triphosphate-sensitive
potassium channel involved in diazoxide cardioprotection. JTCVS Open 2023;15:231-41. DOI PubMed PMC
60. Anastacio MM, Kanter EM, Makepeace C, et al. Cardioprotective mechanism of diazoxide involves the inhibition of succinate
dehydrogenase. Ann Thorac Surg 2013;95:2042-50. DOI PubMed PMC